Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

Inclusion Criteria:

Diagnosed with plaque-type psoriasis defined by either:

A board-certified dermatologist, OR
Dermatology Nurse Practitioner, OR
Skin punch biopsy
Involvement of body surface area (BSA) < 10% at screening and baseline visit.

The presence of plaque-type psoriasis at least two (2) plaques that are at least two (2) cm² in areas of the trunk, buttock, or extremities that are either:

Symmetrically located on contralateral body site OR
Within the same body site but separated by ≥ 1 cm
Able to give informed consent under IRB approval procedures

Exclusion Criteria:

Known allergy or hypersensitivity to triamcinolone acetonide
Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.
Inability to provide informed consent
Active untreated diseases or medication usage which may interfere with wound healing and immune function (anti-neoplastic, systemic immunosuppressants, anticoagulants, daily NSAIDS)
Use of tanning booths for at least 4 weeks prior to baseline visit
Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit
Current or recent use of systemic or biologic therapy for at least 4 weeks or 5 half-lives of the drug (whichever is longer) prior to baseline visit